BR112020010149A8 - Derivado de pirimidina sulfamida e método de preparação e aplicação médica - Google Patents

Derivado de pirimidina sulfamida e método de preparação e aplicação médica

Info

Publication number
BR112020010149A8
BR112020010149A8 BR112020010149A BR112020010149A BR112020010149A8 BR 112020010149 A8 BR112020010149 A8 BR 112020010149A8 BR 112020010149 A BR112020010149 A BR 112020010149A BR 112020010149 A BR112020010149 A BR 112020010149A BR 112020010149 A8 BR112020010149 A8 BR 112020010149A8
Authority
BR
Brazil
Prior art keywords
preparation
derivative
pyrmidine
sulfamide
medical application
Prior art date
Application number
BR112020010149A
Other languages
English (en)
Other versions
BR112020010149A2 (pt
Inventor
Luo Yunfu
Lei Maoyi
Li Junmiao
Xu Yu
Wei Ran
Chen Shuhui
Original Assignee
Shijiazhuang Sagacity New Drug Dev Co Ltd
Wuxi Biocity Biopharmaceutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shijiazhuang Sagacity New Drug Dev Co Ltd, Wuxi Biocity Biopharmaceutics Co Ltd filed Critical Shijiazhuang Sagacity New Drug Dev Co Ltd
Publication of BR112020010149A2 publication Critical patent/BR112020010149A2/pt
Publication of BR112020010149A8 publication Critical patent/BR112020010149A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

São descritas séries de compostos de pirimidina sulfamida e aplicações das mesmas no preparo de um fármaco para uma doença relacionada a um antagonista do receptor ETA. Em particular, é descrito um composto derivado representado pela fórmula (I) ou um tautômero ou composição farmaceuticamente aceitável do mesmo.
BR112020010149A 2017-11-21 2018-11-19 Derivado de pirimidina sulfamida e método de preparação e aplicação médica BR112020010149A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711168111.3 2017-11-21
CN201711168111 2017-11-21
PCT/CN2018/116196 WO2019101039A1 (zh) 2017-11-21 2018-11-19 嘧啶磺酰胺类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
BR112020010149A2 BR112020010149A2 (pt) 2020-11-10
BR112020010149A8 true BR112020010149A8 (pt) 2023-01-17

Family

ID=66630436

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020010149A BR112020010149A8 (pt) 2017-11-21 2018-11-19 Derivado de pirimidina sulfamida e método de preparação e aplicação médica

Country Status (19)

Country Link
US (1) US11319305B2 (pt)
EP (1) EP3719013B1 (pt)
JP (1) JP7245832B2 (pt)
CN (1) CN111479808B (pt)
AU (1) AU2018372752B2 (pt)
BR (1) BR112020010149A8 (pt)
CA (1) CA3083019A1 (pt)
DK (1) DK3719013T3 (pt)
ES (1) ES2936864T3 (pt)
FI (1) FI3719013T3 (pt)
HR (1) HRP20230318T1 (pt)
HU (1) HUE061515T2 (pt)
IL (1) IL274773B2 (pt)
LT (1) LT3719013T (pt)
PL (1) PL3719013T3 (pt)
PT (1) PT3719013T (pt)
RS (1) RS64040B1 (pt)
SI (1) SI3719013T1 (pt)
WO (1) WO2019101039A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109232546B (zh) * 2018-09-25 2020-09-04 中国人民解放军总医院 一种嘧啶磺酰胺类衍生物的医药用途
BR112021023328A8 (pt) * 2019-05-22 2023-04-25 Shijiazhuang Sagacity New Drug Dev Co Ltd Forma de cristal de composto de pirimidina sulfonamida e método de preparação para a mesma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
CA2348847A1 (en) * 2000-05-31 2001-11-30 Pfizer Inc. New isoxazole-sulfonamide endothelin antagonists
JP3490959B2 (ja) 2000-07-11 2004-01-26 三洋電機株式会社 受光素子及び受光モジュール
US7094781B2 (en) 2000-12-18 2006-08-22 Actelion Pharmaceuticals Ltd. Sulfamides and their use as endothelin receptor antagonists
KR101063042B1 (ko) 2002-12-02 2011-09-07 액테리온 파마슈티칼 리미티드 피리미딘-설파마이드 및 엔도텔린 수용체 길항제로서이들의 용도
TW200628467A (en) 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides

Also Published As

Publication number Publication date
HUE061515T2 (hu) 2023-07-28
US11319305B2 (en) 2022-05-03
IL274773A (en) 2020-07-30
CN111479808B (zh) 2023-02-24
EP3719013B1 (en) 2023-01-04
BR112020010149A2 (pt) 2020-11-10
RU2020119900A3 (pt) 2021-12-23
JP2021504330A (ja) 2021-02-15
PL3719013T3 (pl) 2023-05-08
RU2020119900A (ru) 2021-12-23
LT3719013T (lt) 2023-05-10
RS64040B1 (sr) 2023-04-28
US20200283425A1 (en) 2020-09-10
WO2019101039A1 (zh) 2019-05-31
CA3083019A1 (en) 2019-05-31
HRP20230318T1 (hr) 2023-05-12
JP7245832B2 (ja) 2023-03-24
AU2018372752A1 (en) 2020-07-02
SI3719013T1 (sl) 2023-05-31
AU2018372752B2 (en) 2023-02-02
ES2936864T3 (es) 2023-03-22
EP3719013A1 (en) 2020-10-07
PT3719013T (pt) 2023-02-01
FI3719013T3 (fi) 2023-04-03
IL274773B2 (en) 2023-08-01
DK3719013T3 (da) 2023-04-03
EP3719013A4 (en) 2021-04-21
CN111479808A (zh) 2020-07-31
IL274773B1 (en) 2023-04-01

Similar Documents

Publication Publication Date Title
CL2018002009A1 (es) Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras.
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
BR112016005270A2 (pt) compostos de aza-piridona, composições farmacêuticas e seus usos
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
WO2015132799A3 (en) Heterocyclic compounds
BR112012027743A2 (pt) ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EA202091256A1 (ru) Новые антагонисты рецептора брадикинина
BR112017004173A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica.
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
PH12018500432A1 (en) Heteroaryl compounds and their use as therapeutic drugs
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
EA201890532A1 (ru) Новые аннелированные бензамиды
NZ731607A (en) Dihydropyrimidin-2- one compounds and medical use thereof
BR112017008794A2 (pt) inibidores de di-heteroaril histona desacetilase e seu uso em terapia
BR112017022757A2 (pt) derivados do pirazol úteis como inibidores da proteína ativadora da 5-lipoxigenase (flap)
BR112017013998A2 (pt) novos derivados de benzimidazol como agentes anti-histamínicos
BR112020010149A8 (pt) Derivado de pirimidina sulfamida e método de preparação e aplicação médica
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25A Requested transfer of rights approved

Owner name: WUXI BIOCITY BIOPHARMACEUTICS CO., LTD. (CN)